The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a
pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of …

Opinion Statement The genomic landscape of metastatic prostate cancer (mPCa) reveals
that up to 90% of patients harbor actionable mutations and> 20% have somatic DNA repair …

Up to 25% of patients with metastatic prostate cancer present with germline or somatic DNA
damage repair alterations, some of which are associated with aggressive disease and poor …

Simple Summary Recent practice-changing trials have highlighted the importance of
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …

Prostate cancer is globally the second most commonly diagnosed cancer type in men.
Recent studies suggest that mutations in DNA repair genes are associated with aggressive …

Simple Summary Prostate cancer still represents an important health problem in men,
considering its high frequency. Over the last decade, novel treatment options have emerged …

Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplastic agents
that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either …

Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …

For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …

Context The goal of precision oncology is to use the underlying genomic characteristics of
the patient and the cancer to select the optimal treatment at a given time. The recent Food …